Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2007-06-12
2007-06-12
Foley, Shanon (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C435S235100, C424S184100, C424S185100, C424S204100, C424S205100
Reexamination Certificate
active
10733582
ABSTRACT:
The invention provides compositions and processes for the production of ordered and repetitive antigen or antigenic determinant arrays. The compositions of the invention are useful for the production of vaccines for the prevention of infectious diseases, the treatment of allergies and the treatment of cancers. Various embodiments of the invention provide for a virus, virus-like particle, viral capsid particle, phage or recombinant form thereof coated with any desired antigen in a highly ordered and repetitive fashion as the result of specific interactions. In one specific embodiment, a versatile new technology based on a cassette-type system (AlphaVaccine Technology) allows production of antigen coated viral particles. Other specific embodiments allow the production of antigen coated hepatitis B virus-like particles or antigen coated Measles virus-like particles.
REFERENCES:
patent: 4722840 (1988-02-01), Valenzuela et al.
patent: 5071651 (1991-12-01), Sabara et al.
patent: 5143726 (1992-09-01), Thornton et al.
patent: 5334394 (1994-08-01), Kossovsky et al.
patent: 5374426 (1994-12-01), Sabara et al.
patent: 5698424 (1997-12-01), Mastico et al.
patent: 5739026 (1998-04-01), Garoff et al.
patent: 5766602 (1998-06-01), Xiong et al.
patent: 5770380 (1998-06-01), Hamilton et al.
patent: 5789245 (1998-08-01), Dubensky, Jr. et al.
patent: 5792462 (1998-08-01), Johnston et al.
patent: 5814482 (1998-09-01), Dubensky, Jr. et al.
patent: 5871747 (1999-02-01), Gengoux-Sedlik et al.
patent: 5916818 (1999-06-01), Irsch et al.
patent: 6004763 (1999-12-01), Gengoux et al.
patent: 6180771 (2001-01-01), Thomas et al.
patent: 6827937 (2004-12-01), Murray
patent: 6964769 (2005-11-01), Sebbel et al.
patent: 0 259 149 (1988-03-01), None
patent: 0 385 610 (1990-09-01), None
patent: 0 425 082 (1991-05-01), None
patent: 0 465 081 (1992-01-01), None
patent: 09202735 (1997-08-01), None
patent: WO 92/11291 (1992-07-01), None
patent: WO 94/06472 (1994-03-01), None
patent: WO 94/15585 (1994-07-01), None
patent: WO 96/05293 (1996-02-01), None
patent: WO 96/30523 (1996-10-01), None
patent: WO 97/31948 (1997-09-01), None
patent: WO 98/15631 (1998-04-01), None
patent: WO 9828624 (1998-07-01), None
patent: WO 99/07839 (1999-02-01), None
patent: WO 99/40934 (1999-08-01), None
patent: WO 99/67293 (1999-12-01), None
Ormstad et al. Clinical and Experimental Allergy 28:702-708, 1998.
Harris et al. international Immunology 9:273-280, 1997.
Miescher et al (Molecular Aspects of Medicing 23:413-462, 2002).
Baba, T. W., et al., “Pathogenicity of Live, Attenuated SIV After Mucosal Infection of Neonatal Macaques,”Science 267:1820-1825 (1995), American Association for the Advancement of Science.
Bachmann, M. F., et al., “Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes,”Eur. J. Immunol. 26:2595-2600 (1996), VCH Verlagsgesellschaft mbH.
Bachmann, M. F. and Zinkemagel, R. M., “The influence of virus structure on antibody responses and virus serotype formation,”Immunol. Today 17: 553-558 (1996). Elsevier Science Ltd.
Bachmann, M. F. and Zinkernagel, R. M., “Neutralizing Antiviral B Cell Responses,”Annu. Rev. Immunol. 15:235-270 (Apr. 1997), Annual Reviews Inc.
Borisova, G., et al., “Hybrid Hepatitis B Virus Nucleocapsid Bearing an Immunodominant Region from Hepatitis B Virus Surface Antigen,”J. Virol. 67:3696-3701 (1993), American Society for Microbiology.
Cesareni, G., “Peptide display on filamentous phage capsids,”FEBS Lett. 307:66-70 (1992), Elsevier Science Publishers B.V.
Clark, H. F., et al., “Comparative Characterization of a C-Type Virus-Producing Cell Line (VSW) and a Virus-Free Cell Line (VH2) fromVipera russelli,” J. Natl. Cancer Inst. 51:645-657 (1973), Oxford University Press.
Connor, R. I., et al., “Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines,”J. Virol. 72:1552-1576 (Feb. 1998), American Society for Microbiology.
Crameri, R. and Suter , M., “Display of biologically active proteins on the surface of filamentous phages: a cDNA cloning system for selection of functional gene products linked to the genetic information responsible for their production,”Gene 137:69-75 (1993), Elsevier Science Publishers B.V.
Daniel, M. D., et al., “Protective Effects of a Live Attenuated SIV Vaccine with a Deletion in thenefGene,”Science 258:1938-1941 (1992), American Association for the Advancement of Science.
Davis, N. L., et al., “In VitroSynthesis of Infectious Venezuelan Equine Encephalitis Virus RNA from a cDNA Clone: Analysis of a Viable Deletion Mutant,”Virology 171:189-204 (1989), Academic Press Inc.
de la Cruz, V. F., et al., “Immunogenicity and Epitope Mapping of Foreign Sequences via Genetically Engineered Filamentous Phage,”J. Biol. Chem. 263:4318-4322 (1988). The American Society for Biochemistry and Molecular Biology Inc.
Donnelly, J. J., et al., “DNA Vaccines,”Annu. Rev. Immunol. 15:617-648 (Apr. 1997), Annual Reviews Inc.
Fehr, T., et al., “Role of Repetitive Antigen Patterns for Induction of Antibodies Against Antibodies,”J. Exp. Med. 185:1785-1792 (May 1997), The Rockefeller University Press.
Förster, E., et al., “Natural and recombinant enzymatically active or inactive bee venom phospholipase A2has the same potency to release histamine from basophils in patients with Hymenoptera allergy,”J. Allergy Clin. Immunol. 95:1229-1235 (1995), Mosby-Year Book, Inc.
Fujiwara, K., et al., “Novel Preparation Method of Immunogen for Hydrophobic Hapten, Enzyme Immunoassay for Daunomycin and Adriamycin,”J. Immunol. Meth. 45:195-203 (1981), Elsevier/North Holland Biomedical Press.
Gilbert, S. C., et al., “A protein particle vaccine containing multiple malaria epitomes,”Nature Biotechnol. 15:1280-1284 (Nov. 1997), Nature Publishing Group.
Greenstone, H. L., et al., “Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model,”Proc. Natl. Acad. Sci. USA 95:1800-1805 (Feb. 1998), The National Academy of Sciences.
Hahn, C. S., et al., “Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation,”Proc. Natl. Acad. Sci. USA 89:2679-2683 (1992), National Academy Press.
Harding, C. V. and Song, R., “Phagocytic Processing of Exogenous Particulate Antigens by Macrophages for Presentation by Class I MHC Molecules,”J. Immunol. 153:4925-4933 (1994), The American Association of Immunologists.
Hilleman, M. R., “Six decades of vaccine development—a personal history,”Nature Med. Vaccine Suppl. 4:507-514 (May 1998), Nature Publishing Group.
Iannolo, G., et al., “Construction, Exploitation and Evolution of a New Peptide Library Displayed at High Density by Fusion to the Major Coat Protein of Filamentous Phage,”Biol. Chem. 378:517-521 (Jun. 1997), Walter de Gruyter & Company.
Iannolo, G., et al., “Modifying Filamentous Phage Capsid: Limits in the Size of the Major Capsid Protein,”J. Mol. Biol. 248:835-844 (1995), Academic Press Limited.
Jiang, X., et al., “Norwalk Virus Genome Cloning and Characterization,”Science 250:1580-1583 (1990), American Association for the Advancement of Science.
Kovacsovics-Bankowski, M., et al., “Efficient major histocampatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophage,”Proc. Natl. Acad. Sci. USA 90: 4942-4946 (1993), National Academy Press.
Kratz, P. A., et al., “Native display of complete foreign protein domains on the surface of hepatitis B virus capsids,”Proc. Natl. Acad. Sci. USA 96:1915-1920 (Mar. 1999). National Academy Press.
Landschulz, W. H., et al., “The Leucine Zipper: A Hypothetical Str
Bachmann Martin
Hennecke Frank
Nieba Lars
Renner Wolfgang A.
Cytos Biotechnology AG
Foley Shanon
Snyder Stuart W.
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Ordered molecular presentation of antigens, method of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ordered molecular presentation of antigens, method of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ordered molecular presentation of antigens, method of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3870222